AXL Inhibitors Market Assessment and Forecast – Competition Landscape, Commercial, and Pipeline Analysis, 2023-2029

Purchase Option

$ 4400
$ 6600
$ 8900

AXL inhibitors are an orally bioavailable and selective inhibitor of the receptor tyrosine kinase AXL (UFO), with potential immunostimulant and antineoplastic activities. This blocks AXL-mediated signal transduction pathways and inhibits both AXL-mediated tumor cell growth, proliferation, migration, and AXL-mediated immunosuppression. AXL is a member of the Tyro 3, AXL, and MERTK (TAM) receptor tyrosine kinase family and is overexpressed by many tumor cell types and expressed in a variety of immune cells including macrophages, natural killer (NK) cells, and regulatory T cells. It plays a key role in tumor cell proliferation, survival, invasion, metastasis, and is a mediator of immunosuppression. AXL inhibitor has a predominant role in treating leukemia, AIDS-HIV, respiratory diseases, bone cancer, CNS neoplasm, and digestive system diseases.

According to World Cancer Research Fund 2020, There were an estimated 18.1 million cancer cases around the world and 4,74,519 new cases of Leukaemia in 2020 and it expected to be 28.4 million cases in 2040, a 47% rise from 2020. Moreover, the launch of newer products by the market players significantly enhances the revenue of AXL inhibitors market over the forecast years. For instance, Exelixis are currently providing AXL inhibitors Cabometyx for the treatment of renal cell carcinoma, Cometriq for the treatment of metastatic medullary thyroid cancer, and Astellas providing Xospata for the treatment of acute myeloid leukemia. Simultaneously, many players developing molecules for treatment of many other tumors. For instance, Mirati’s MGCD516 for cancer, BerGenBio’s BGB324 for resistant cancer, Eli Lilly’s LY2801653 for advanced biliary tract cancer, Pfizer’s PF-07265807 for solid tumor, and Roche’s RXDX-106 for metastatic solid tumors are under the various stages of clinical studies.

Key Market Developments:

  • In September 2021, FDA approved Cabometyx (Cabozantinib), for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer.
  • In April 2021, GlaxoSmithKline agreed to sell its royalty stake to Royalty Pharma in two Cabozantinib drugs under the trade names Cabometyx and Cometriq.

Approved Drug Molecules with Brand Names for AXL Inhibitors:

  • Cabometyx (Cabozantinib tablet)  - Exelixis
  • Cometriq (Cabozantinib capsule) - Exelixis
  • Xospata (Gilteritinib) - Astellas

Drugs under the Pipeline for AXL Inhibitors:

  • Sitravatinib (MGCD516) - Mirati
  • Bemcentinib (BGB324) - BerGenBio
  • Merestinib (LY2801653) - Eli Lilly
  • Glesatinib (MGCD265) - Mirati
  • AL2846 - Advenchen, Sino Biopharm
  • SLC-391 - SignalChem Lifesci
  • Zanzalintinib (XL092) - Exelixis
  • PF-07265807 - Pfizer
  • RXDX-106 - Roche

Clinical Activity and Developments of AXL Inhibitors:

As of June 2023, more than 30 companies have approximately 30 molecules for above 130 diseases. For these molecules, more than 240 clinical trials are being conducted by the players across the globe. For instance,

  • In 2019, in Phase 3, ADMIRAL Trial Data Show XOSPATA (Gilteritinib) Significantly increases Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed Acute Myeloid Leukemia
  • In August 2022, Cabozantinib and checkpoint inhibitors Atezolizumab demonstrated significant clinical activity in COSMIC-312 trial for advanced hepatocellular carcinoma.

Molecule Name

Number of Studies

Sitravatinib (MGCD516)


Bemcentinib (BGB324)


Batiraxcept (AVB-500)


Merestinib (LY2801653)


Glesatinib (MGCD265)


Target Indication Analysis of AXL inhibitors

The molecules such as Cabometyx (Cabozantinib tablet) for the treatment of renal cell carcinoma,  and  Cometriq (cabozantinib capsule) for the treatment of metastatic medullary thyroid cancer  developed by  Exelixis. Moreover, Xospata (Gilteritinib) for treatment of acute myeloid leukemia developed by Astellas are currently in the market. Increase in the incidence of leukemia, carcinoma and other cancers is expected to create opportunity for the AXL inhibitor market. Besides, Opdivo (nivolumab) and Cabometyx (Cabozantinib) in combination have been approved by the European Commission for use as the first-line treatment for patients with advanced renal cell carcinoma.

Frequently Asked Questions

Cabometyx (cabozantinib tablet), Cometriq (cabozantinib capsule), Xospata (gilteritinib) are the approved AXL inhibitors.

Global sales for cabozantinib by Exelixis and its collaboration partners Ipsen pharma and Takeda in the FY2022 was US$ 1.9 billion.

Major market players include Exelixis,Inc., Astellas Pharma Inc, Eli Lilly and Co., Pfizer Inc., Advenchen, BerGenBio ASA, and Roche Ltd are a few leading market players.

Development of novel molecules for leukemia and other cancer diseases create lucrative opportunities for the AXL inhibitors market over the forecast years.

Major Indications for AXL inhibitors are Leukemia, Carcinoma, Respiratory diseases, Bone cancer,CNS neoplasm and Digestive system diseases.

There are a total of 28 molecules that are in the Phase-1/Phase-2 clinical development for AXL inhibitors.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Exelixis,Inc. (USA)
  • Astellas Pharma Inc.(USA)
  • Mirati (USA)
  • BerGenBio ASA (USA)
  • Aravive (USA)
  • Eli Lilly and Co. (USA)
  • HEC Pharma (China)
  • Advenchen (USA)
  • Ono Pharma co.Ltd (Japan)
  • Incyte (USA)
  • Pfizer Inc.(USA)
  • Roche Ltd (Switzerland)
  • Servier (France)
  • Oscotec (South korea)

Adjacent Markets